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Isohomohalichondrin B (IHB) is a polyether macrolide (Figure 1)
isolated from the Lissodendoryx sponge and shows in vitro cyto-
toxic activity against a variety of human cancer cell lines (Hirata
and Uemura, 1986) and, more recently, in vivo anti-tumour activity
against murine tumours and human tumours transplanted in nude
mice (unpublished data). The drug was initially tested in the NCI
tumour cell lines screening panel and was found to be effective in
inhibiting cell growth at concentrations ranging from 10–9 to 10–5 M
(unpublished data made available by the NCI). The NCI compara-
tive analysis showed a significant correlation between the pattern
of sensitivity of IHB to that of other anti-tubulin drugs such as the
vinca alkaloids vincristine and vinblastine and maytansine.
These data are in good agreement with biochemical studies
indicating that IHB binds to tubulin, inhibiting GTP binding and
preventing microtubule assembly (García-Rocha et al, 1996).
As IHB is a strong potential candidate for clinical investigation,
it is of interest to characterize further its mode of action and its
pharmacological properties.
In the present study, the in vitro effect of IHB on the cell cycle
and the mechanism of cell death have been investigated using
selected human cancer cell lines.
MATERIALS AND METHODS
Cells and culture conditions
Human leukaemic K562 and MOLT-4 cell lines were grown in
suspension in RPMI-1640 medium (Gibco Europe, Paisley, UK)
containing 10% heat-inactivated fetal bovine serum (FBS)
(Mascia Brunelli SPA, Milan, Italy) in T-25-cm2 tissue culture
flasks (Costar–Corning–Nucleopore, Cambridge, MA, USA).
Human colon LoVo and LoVo/DX were grown in monolayer
culture in F-12 (Ham) medium supplemented with 15% FBS and
1% vitamins in T-25-cm2 tissue culture flasks in standard culture
conditions.
Drug treatment
IHB was provided by PharmaMar. Exponentially growing LoVo,
LoVo/DX, MOLT-4 and K562 cells were treated for 1 h with
different concentrations of IHB. The shorter exposure time was
chosen in order to evaluate more precisely the time course of the
cell cycle perturbations induced by the drug. After treatment, the
medium was removed and the cells were washed with phosphate-
buffered saline (PBS) and provided with fresh medium. At
different times after drug washout, the cells were counted with a
Coulter counter (model ZM; Luton, UK), fixed in 70% ethanol and
kept at 4°C before analysis by flow cytometry. For 5-bromo-2¢-
deoxyuridine (BrdU)/DNA biparametric analysis during the last
Cell cycle perturbations and apoptosis induced by
isohomohalichondrin B (IHB), a natural marine compound
D Bergamaschi1, S Ronzoni1, S Taverna1, M Faretta1, P De Feudis1, G Faircloth2, J Jimeno3, E Erba1 and M D’Incalci1
1Cancer Pharmacology Laboratory, Department of Oncology, Istituto di Ricerche Farmacologiche ‘Mario Negri’, via Eritrea 62 – 20157 Milan, Italy; 2PharmaMar
USA, Inc., 26 Landsdowne Street, Cambridge MA, USA; 3PharmaMar SA, Research and Development, c/Caldera, 3, 28760 Tres Cantos, Madrid, Spain
Summary Isohomohalichondrin B (IHB), a novel marine compound with anti-tumoral activity, extracted from the Lissodendorix sponge,
inhibits GTP binding to tubulin, preventing microtubule assembly. Cell cycle perturbations and apoptosis induced by IHB were investigated on
selected human cancer cell lines by using flow cytometric and biochemical techniques. Monoparameter flow cytometric analysis showed that
1 h IHB exposure caused a delayed progression through S-phase, a dramatic block in G2M phase of the cell cycle and the appearance of
tetraploid cell population in LoVo, LoVo/DX, MOLT-4 and K562 cells. At 24 h after IHB exposure, the majority of cells blocked in G2M were in
prophase as assessed by morphological analysis and by the fact that they expressed high levels of cyclin A/cdc2 and cyclin B1/cdc2. At 48 h,
all cells were tetraploid as assessed by biparameter cyclin A/DNA and cyclin B1/DNA content analysis. Apoptotic death was detected in both
leukaemic MOLT-4 and K562 cells, which express wild-type and mutated p53 respectively, when the cells were blocked in mitotic prophase.
In conclusion, IHB is a novel potent anti-tumour drug that causes delayed S-phase progression, mitotic block, tetraploidy and apoptosis in
cancer cell lines.
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Figure 1 IHB chemical structure15 min of treatment, the cells were treated with 30 mM BrdU. After
treatment, the medium was removed, the cells washed with PBS
and provided with fresh medium. At different times after drug
washout the cells were counted and fixed as described previously
(Erba et al, 1995).
DNA staining
The fixed cells were washed with cold PBS and stained with 2 ml of
propidium iodide (PI) solution containing 25 mg ml–1 PI in PBS plus
25 ml of RNAase (Calbiochem, La Lolla, CA, USA), 1 mg ml–1 in
water, for 60–120 min at room temperature in the dark.
BrdU/DNA staining
For detection of BrdU incorporation into DNA, the fixed cells were
washed with cold PBS and the DNA was denatured with 1 ml of 3 M
hydrogen chloride for 20 min at room temperature to allow the anti-
BrdU Mab to react with the BrdU incorporated in the DNA chain.
DNA denaturation was stopped by adding 3 ml of 0.1 M sodium
tetraborate pH 8.5. After centrifugation, the pellet was incubated with
1 ml of 0.5% Tween-20 (Sigma Chemical, St Louis, MO, USA) in
PBS and 1% normal goat serum (NGS) (Dakopatts, Denmark) for
15 min at room temperature. The incorporated BrdU was visualized
by incubating the cells with the anti-BrdU Mab (Becton Dickinson,
Sunnyvale, CA, USA) diluted 1:10 in 0.5% Tween-20 in PBS for 1 h
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Figure 2 Effects of IHB on the cell cycle phase distribution evaluated at 6, 24 and 48 h after drug washout. (A) LoVo cells: a, control; b, IHB 1 nM; c, IHB 2 nM.
(B) LoVo/DX cells: a, control; b, IHB 2.5 nM; c, IHB 10 nM. (C) MOLT-4 cells: a, control; b, IHB 0.5 nM; c, IHB 1 nM; d = IHB 2 nM. (D) K562 cells: a, control;
b, IHB 0.5 nM; c, IHB 1 nM; d = IHB 2 nMat room temperature in the dark. After centrifugation, the pellet was
incubated with 1 ml of 0.5% Tween-20 and 1% NGS for 15 min at
room temperature. Then, the cells were incubated with a fluorescein
isothiocyanate (FITC)-conjugated affinipure F(ab¢)2 fragment of
goat anti-mouse IgG MAb (Jackson Immuno Research Laboratories,
USA) diluted 1:50 in 0.5% Tween-20 in PBS for 1 h at room temper-
ature in the dark. The cells were finally resuspended in 2 ml of PI
solution containing 2.5 mg ml–1 PI in PBS and 25 ml of RNAase,
1 mg ml–1 in water (Calbiochem, La Lolla, CA, USA) and stained
overnight at 4°C in the dark (Erba et al, 1995).
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Figure 3 Biparametric BrdU/DNA flow cytometric analysis of (A) MOLT-4 control and (B) IHB-treated cells evaluated at different time intervals after drug
washout
0 h 3 h 6 h 12 h 24 h 48 h
200 400 200 400 200 400 200 400 200 400 200 400
200 400 200 400 200 400 400 800 400 800
FL3-H
DNA content
10
3
10
2
10
1
10
3
10
2
10
1
10
4
B
r
d
U
 
c
o
n
t
e
n
t
F
L
1
-
H
F
L
1
-
H
FL3-H FL3-H FL3-H FL3-H
A
B
10
4
Figure 4 Biparametric BrdU/DNA flow cytometric analysis of (A) K562 control and (B) IHB-treated cells evaluated at different time intervals after drug washout
A
BMonoparametric DNA and biparametric BrdU/DNA analysis
were performed on at least 20 000 cells for each sample by the
FacSort system (Becton Dickinson). The data are the average of
three replications and were analysed with Cell Quest software.
The fluorescence pulses were detected using a bandpass filter,
530 ± 30 nm and 620 ± 35 nm for green and red fluorescence
respectively, in combination with a 570-nm dichroic mirror. The
percentage of the cell cycle phase distribution was calculated by
the method of Krishan and Frei (1976).
Cyclins A and B1/DNA staining
At the end of treatment, and at different time intervals after drug
washout, the cells were fixed in 70% ethanol and stored at 4°C.
The fixed cells were washed in cold PBS and permeabilized with
0.25% Triton X-100 (Sigma, St Louis, MO, USA) in PBS for
5 min in ice. Then, cells were washed in PBS and incubated with
200 ml of anti-human cyclin A, BF683 clone, or anti-human cyclin
B1 monoclonal antibody, GNS-11 clone (Pharmingen, San Diego,
CA, USA), at a concentration of 2.5 mg ml–1 in PBS + 1% NGS
overnight at 4°C in the dark. A blank sample was prepared by
incubation of cells with 200 ml of 1% NGS in PBS or with the
isotype IgG instead of the cyclin. After removing the MAb, the
cells were incubated with 200 ml of FITC-conjugated affinipure
F(ab¢)2 fragment of goat anti-mouse IgG MAb diluted 1:50 in
0.5% Tween-20 in PBS for cyclin B1 and FITC-conjugated rat
anti-mouse IgE for cyclin A for 1 h at room temperature in the
dark. The cells were finally resuspended in 2 ml of PI solution
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Figure 5 Percentage of cells in relation to different DNA and BrdU content. (A) BrdU– 2N cells (diploid G1). (B) BrdU+ 2N cells (diploid G1). (C) BrdU– 4N cells
(diploid G2M and G1 tetraploid IHB-treated cells). (D) BrdU+ 4N cells (diploid G2M and G1 tetraploid IHB-treated cells). (E) BrdU– 8N cells (G2M cells of the new
tetraploid cell population). (F) BrdU+ 8N cells (G2M cells of the new tetraploid cell population). Continuous line, control cells; dotted line, IHB-treated cellscontaining 2.5 mg ml–1 PI in PBS and 25 ml of RNAase, 1 mg ml–1
in water, and stained overnight at 4°C in the dark (Gong et al,
1995; Faretta et al, 1997).
Apoptosis/DNA staining
Cell fixation and permeabilization were performed as described for
cyclin staining. Briefly, after removing Triton X-100, the cells were
incubated in 50 ml of solution containing terminal-dUTP-transferase
(TdT) and FITC-conjugated dUTP deoxynucleotides 1:1 in storage
buffer (Boehringer Mannheim, Germany) for 60 min at 37°C in the
dark. This test is based on labelling of DNA strand breaks resulting
from internucleosomal cleavage by a calcium-dependent endo-
nuclease, activated during cell death. TdT catalyses the incorpora-
tion of FITC-conjugated nucleotides to the 3¢-OH free DNA ends in
a template-independent manner. After washing in PBS, the cells
were analysed by flow cytometry or were stained with PI solution
containing 1–2 mg ml–1 PI in PBS and 25 ml of RNAase, 1 mg ml–1 in
water, and stained overnight at 4°C in the dark (Li et al, 1995).
Gel electrophoresis
DNA fragmentation was measured by gel electrophoresis. Briefly,
106 cells were lysed in lysis buffer (5 mM Tris-HCl, pH 8; 10 mM
Isohomohalichondrin B induces mitotic block and apoptosis 271
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Figure 6 Biparametric cyclin A/DNA flow cytometric analysis of (A) MOLT-4 and (B) K562 cells treated with 2 nM IHB for 1 h evaluated at different time
intervals after drug-washout. a, control cells; b, IHB-treated cellsEDTA, pH 8; 0.5% Triton X-100) for 10 min on ice. The lysate
was centrifuged at 12 000 g for 20 min at 4°C to remove high
molecular-weight DNA. The supernatant, containing degraded
DNA, RNA and cellular proteins was incubated for 1 h at 37°C
with 100 mg ml–1 RNAase and for 2 h at 50°C with 100 mg ml–1
proteinase K. After phenol, phenol–chloroform and chloroform
extraction, DNA was precipitated in ethanol, dried and resus-
pended in gel loading buffer. Samples were loaded on 1.5%
agarose gel and DNA ladders were visualized by ethidium-
bromide staining (Cohen et al, 1992).
Immunoprecipitation
Total cell extracts were prepared from MOLT-4 and K562 after
1 h of drug treatment and at 24 h after drug washout according
to standard procedures (O’Connor et al, 1993). One hundred
micrograms of protein from untreated or drug-treated cells
was immunoprecipitated with antibodies specific for cdc2
(Santa Cruz Biotechnology) and collected by binding to
protein A–Sepharose. After three washes in lysis buffer and two in
kinase buffer, complexes were resuspended in 30 ml of kinase
buffer.
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Figure 7 Biparametric cyclin B1/DNA flow cytometric analysis of (A) MOLT-4 and (B) K562 cells treated with 2 nM IHB for 1 h evaluated at different time
intervals after drug washout. a, control cells; b, IHB-treated cells
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BIn vivo kinase assay
Kinase activity was measured by incubating 100 ng of immuno-
precipitated complexes containing cyclin B-cdc2 at 30°C for
20 min in a total volume of 25 ml of kinase buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 10 mM magnesium
chloride, 1 mM DTT) containing 2 mg of histone H1, 1 mM ATP
and 5 mCi of [g-32P]ATP (5000 Ci mmol–1; Amersham); 25 ml of 2
´ SDS-loading buffer were added and the samples were boiled and
loaded on 12% SDS-PAGE. Histone H1 was loaded as a marker of
molecular weight and separately stained with Coomassie blue
(Bonfanti et al, 1997).
RESULTS
Figure 2 shows a monoparametric assessment of cell cycle distrib-
ution of LoVo, LoVo/Dx, MOLT-4 and K562 cells exposed for 1 h
to IHB at a concentration that caused a similar growth inhibition.
MOLT-4 and K-562 were the most sensitive, with GI50 being
approximately 1 nM; in LoVo and LoVo/Dx, GI50 values were
approximately 2 and 10 nM respectively.
IHB induced (1) an early accumulation of cells in S-phase, more
evident in LoVo and MOLT-4 cells; (2) an accumulation of cells in
G2M, evident in all cell lines at 24 h; and (3) the appearance of
cells with an increased DNA content, above that of G2M phase
Isohomohalichondrin B induces mitotic block and apoptosis 273
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Figure 8 Evaluation of the activity of the cyclin A and cyclin B1/Cdc2 complex quantitated by densitometric analysis of the radioactive films in (A) K562 and
(B) MOLT-4 cells
Figure 9 Detection of apoptosis in (A) MOLT-4 and (B) K562 cells. Cells were treated for 1 h with IHB and biparametric scatter (FSC-H)/TdT-dUTP analysis
was performed at different times after drug washout. a, control cells; b, 0.1 nM IHB; c, 0.5 nM IHB; d, 1 nM IHB
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a bc d a bc dcells, which became evident at 48 h. In order to obtain a dynamic
evaluation of the drug-induced cell cycle perturbation, further
experiments were conducted using a biparametric analysis of the
cell cycle by means of the combined use of the BrdU/DNA
staining procedure in two out of the four cell lines initially investi-
gated, MOLT-4 and K562. As BrdU was given in the last 15 min
of the 1-h incubation period with 2 nM IHB, it was possible to
obtain a distinct evaluation of the cell cycle perturbations in cells
that occurred in S-phase during drug treatment (BrdU+ cells) and
of cells that were in other phases of the cell cycle (BrdU– cells). As
seen in Figures 3 and 4, 3 h after IHB washout, those cells which
were in the S-phase (BrdU+ cells) during drug treatment,
progressed through this phase of the cell cycle more slowly than
control cells. Those cells which were in the G2M phase (BrdU–
cells) during drug treatment remained in G2M. At 6 h after IHB
washout, some BrdU+ cells were still in S-phase, whereas others
were blocked in the G2M phase. At the same time, in control cells,
a fraction of cells that started a new cell cycle was clearly evident.
At 12 h after IHB washout, all the BrdU+ cells were blocked in the
G2M phase of the cell cycle, whereas the BrdU– cells slowly
progressed from the S phase. At 24 h, the BrdU+ and the BrdU–
cells were blocked in the G2M phase of the cell cycle and a new
population with a tetraploid DNA content appeared. At 48 h after
IHB washout, the majority of the treated cells had a tetraploid
DNA content. Figure 5 shows the percentage of 2N, 4N and 8N
cell populations in relation to their BrdU content. Between 24 and
48 h after IHB washout most of the treated cells were blocked in
mitosis and some of them divided abnormally, giving rise to a new
tetraploid cell population, more evident at 48 h after IHB washout.
For this reason, in Figure 5 C and D, the percentage of 4N BrdU–
and BrdU+ IHB-treated cells, evaluated 24 and 48 h after drug
washout, include G2M cells of the diploid population and G1 cells
of the new tetraploid cell population.
The biparametric cyclins/DNA analysis were then performed to
characterize more precisely the cell cycle phase perturbations
induced by IHB.
Figure 6 shows the levels of cyclin A in MOLT-4 and K562 cells at
different time intervals after 2 nMIHB treatment. The levels of cyclin
A were not changed compared with control cells, thus excluding the
possibility that the slow progression of IHB treated cells through the
S-phase was due to changes in the levels of this cyclin. At 12 h after
drug washout, a fraction of the cyclin A-negative cell population
(56% in MOLT-4, 52% in K562) was evident, indicating that IHB
treated cells started to be blocked in mitosis. At 24 h after drug treat-
ment, nearly all the cells blocked in G2M were cyclin A negative
(86% in MOLT-4, 84% in K562), thus indicating that all cells were
blocked in mitosis and not in the G2 phase of the cell cycle.
Figure 7 shows the levels of cyclin B1 in Molt-4 and in K562
cells at different time intervals after IHB treatment. As expected,
when the treated cells started to accumulate in the G2M phase of
the cell cycle, the fraction of cyclin B1-positive cells increased.
However, as shown for cyclin A, IHB did not cause marked
changes in the levels of cyclin B1. It is interesting to note that, at
48 h after drug washout, all cells with a DNA content corre-
sponding to G2M phase cells were cyclin B1 negative, indicating
that at this time no G2M phase cells were present but only G1 cells
of the new tetraploid population caused by an abnormal mitosis
related to IHB treatment.
Consistent with the fact that IHB blocks cells at the beginning
of mitosis is the finding that both MOLT-4 or K562 cells main-
tained high levels of cyclin B1/cdc2 or cyclin A/cdc2 kinase
activity as shown in Figure 8.
The data presented above indicate that the mitotic block
observed within 24 h for IHB treatment was no longer present at
48 h, when the tetraploid cell population became prevalent.
Following these observations, we then investigated the mecha-
nism of cell death induced by IHB. IHB induced apoptosis in both
MOLT-4 and K562 cells, even if the level of apoptotic cells was
different between the two cell lines. Figure 9 shows the results
of experiments performed to detect apoptosis by using the
TdT–dUTP test. At 72 h in MOLT-4 cells the amount of apoptotic
cells corresponding to 15% at the IHB concentration of 0.1 nM
increased to 50% and then 85% at concentrations of 0.5 and 1 nM
respectively. In K562 cells at 72 h after IHB washout, only 20% of
the treated cells were apoptotic.
By combining TdT–dUTP with DNA staining, it is possible to
identify the cell cycle phase position of apoptotic cells. As seen
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Figure 10 Detection of apoptosis in MOLT-4 treated with 2 nM IHB for 1 h
evaluated at different time intervals after drug washout. (A) Biparametric
scatter FSC-/TdT-dUTP analysis. (B) DNA histograms related to viable cells
or apoptotic cells. White DNA histograms, control untreated cells. (a) Grey
DNA histograms, viable treated cells at 24 (b) or 72 (c) h after drug washout.
Black DNA histograms, apoptotic treated cells at 24 (b) or 72 (c) h after drug
washoutfrom Figure 10, 24 h after drug washout the majority of the IHB-
treated MOLT-4 cells were blocked in mitosis, as clearly shown by
the grey DNA histogram. At this time the incorporation of TdT-
dUTP was selective to the fraction of cells blocked in mitosis, as
shown by the black DNA histogram. At 72 h after drug washout,
the majority of the treated cells were positive for the TdT–dUTP
test, as shown by the black DNA histogram; these cells were
blocked in G2M phases or had an increased DNA content above
that of the G2M phase cells. At this time, few non-apoptotic cells,
with a cell cycle phase distribution similar to the control cells,
were detected (grey DNA histogram). Figure 11A and B shows
IHB-induced apoptosis determined by 4¢,6-diamidino-2-phenyl-
indole (DAPI) and sulphorhodamine 101 staining. IHB induced
morphological changes associated with apoptosis, nuclear conden-
sation and formation of apoptotic bodies, and cells blocked in
prophase were clearly evident (Figure 11B, upper panel). At later
time points, the number of apoptotic cells increased (Figure 11,
lower panel). Further demonstration of apoptosis was obtained by
looking at DNA laddering, as shown in Figure 12. In MOLT-4
cells, DNA fragmentation was evident at 0.5 and 1 nM IHB at both
24 and 48 h after IHB washout, whereas in the K562 cells DNA
fragmentation was not evident until 48 h after drug washout and
only at a concentration of 1 nM.
DISCUSSION
The present study reports the perturbations of the cell cycle and the
mechanism of cell death induced by IHB, a novel marine-derived
anti-tumour compound. The observed effects, which can be
summarized as a delayed progression through S-phase, a G2M
block and the appearance of a tetraploid population, may well be
related to the previously reported data indicating that IHB targets
the tubulin network (García-Rocha et al, 1996). García Rocha et al
(1996) reported that 2 mM IHB inhibited in vitro tubulin polymer-
ization. The same authors reported that 7 mM IHB for 2 h signifi-
cantly disrupted the microtubule cytoskeleton of COS-1 cell line
as assessed by morphological examination after tubulin staining. It
is possible that both S-phase delayed progression and the G2M
block observed in the present study are related to these biochem-
ical effects reported by García-Rocha et al (1996). However, it
should be noted that the IHB concentrations used in this study
were at least 1000 times lower than those used in the mentioned
studies. The discrepancy between high cytotoxic potency (IC50 in
nM range) and weak inhibition of in vitro tubulin polymerization
(Ki in mM range) has already been described for the structurally
similar compound, homohalichondrin B (Bai et al, 1991). These
authors also characterized the ability of this compound to inhibit
tubulin-dependent GTP hydrolysis, but have not provided any
explanation for the relatively high concentrations required for the
in vitro effects. It might be that the inhibition of tubulin polymer-
ization is dependent upon other factors present in intact cells, but
not in the in vitro assays. Alternatively, other mechanisms of cyto-
toxicity should be considered.
There is little knowledge on the binding of IHB to tubulin,
whereas much more information is available for homohalichondrin
B, which is structurally similar to IHB. Luduena et al (1993) found
that homohalichondrin B has a distinct mechanism of interaction
with tubulin molecules compared with vinca alkaloids, maytan-
sine, dolastatin 10 or phomopsin A. In particular, homohalichon-
drin B differed from other anti-mitotic drugs in that it enhanced
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Figure 11 UV light photomicrographs of MOLT-4 and K562 cells untreated or treated with 2 nM IHB. (A) Control cells; (B) IHB-treated cells. a, apoptotic cells
with fragmented nuclei. b, cells blocked in mitosisexposure of hydrophobic areas on tubulin. It remains to be estab-
lished if these differences also apply to IHB and if they are rele-
vant in determining differences in the pharmacological properties
between this compound and the other inhibitors of tubulin (Jordan
et al, 1991).
A particularly striking finding of the present study is that IHB
induces both the appearance of a tetraploid cell population and
apoptosis. The mechanism of induction of polyploidy by drugs is
generally poorly understood (Watters et al, 1994; Cross et al,
1995). It has recently been reported that the expression of mutated
p53 or the loss of wild-type (wt) p53 induces the appearance of
polyploid cells following g-irradiation (Peled et al, 1996). In the
present study, we found that IHB was able to induce polyploidy in
both wt p53-expressing cells, such as LoVo and MOLT-4 cells, and
in cells not expressing p53, such as K562 cells. Therefore, the
induction of polyploidy by IHB does not appear to be mediated by
p53 expression.
Nor can we draw any conclusion regarding the role of p53 in
IHB-induced apoptosis. In fact, we found that IHB induced apop-
tosis to a much greater extent in MOLT-4 cells, which express wt
p53, than in K562 cells and markedly increased the expression of
this protein after IHB exposure (data not shown). It should also be
noted, however, that in the K562 leukaemic cell line a fraction of
apoptotic cells was observed after IHB treatment, but not with
other anti-cancer drugs, e.g. cis-DDP (data not shown). It appears,
therefore, that IHB-induced apoptosis is not necessarily or totally
p53 dependent, as is the case for other anti-cancer agents (Strasser
et al, 1994; De Feudis et al, 1996).
In conclusion, the present study reports the first characterization
of cell cycle perturbation and cell death mechanism by the novel
marine natural product IHB. This compound has been recently
seen to be active in vivo against rodent tumours and human
xenografts and is a potential candidate drug for clinical studies. In
the past, the clinical development of halichondrin B has been
hampered by the very low availability of this natural product. The
greater availability of IHB makes this compound more accessible
for preclinical development and to identify appropriate tumour
targets for the clinic.
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